Although global abnormalities in white matter and grey matter are not associated with cannabis abuse, reduced hippocampal volume is consistently found. Amygdalar abnormalities are sometimes reported, although findings are inconsistent. Preliminary evidence suggests that this effect is largely mediated by THC, and that CBD may even have a protective effect.
In late 2017, researchers with the University of Guelph in Canada published the first-ever study to document the ideal growing conditions for cannabis. Using liquid organic fertilizer with a PKN ratio of 1.3P–1.7K-4.0N, the experiment tested five increasing rates of fertilization. They also tested two coir-based soil-less growing media, or “substrates.”
Along with its better-known counterpart, THC (delta-9-tetrahydrocannabinol, the chemical that produces the marijuana high), CBD is one of more than 400 compounds found in the oils of cannabis plant species, which include marijuana and hemp. Unlike THC, CBD will not make you high. That said, this doesn’t mean CBD is not at all psychoactive, as many assert, says Jahan Marcu, Ph.D., director of experimental pharmacology and behavior at the International Research Center on Cannabis and Mental Health in New York City: “CBD does change cognition. It affects mood, which is why people take it for anxiety. And some find that it makes them more alert.”
Another study examined the effects of a plant extract with controlled cannabinoid content in an oromucosal spray. In a multicenter, double-blind, placebo-controlled study, the THC:CBD nabiximols extract and THC extract alone were compared in the analgesic management of patients with advanced cancer and with moderate-to-severe cancer-related pain. Patients were assigned to one of three treatment groups: THC:CBD extract, THC extract, or placebo. The researchers concluded that the THC:CBD extract was efficacious for pain relief in advanced cancer patients whose pain was not fully relieved by strong opioids. In a randomized, placebo-controlled, graded-dose trial, opioid-treated cancer patients with poorly controlled chronic pain demonstrated significantly better control of pain and sleep disruption with THC:CBD oromucosal spray at lower doses (1–4 and 6–10 sprays/day), compared with placebo. Adverse events were dose related, with only the high-dose group (11–16 sprays/day) comparing unfavorably with the placebo arm. These studies provide promising evidence of an adjuvant analgesic effect of THC:CBD in this opioid-refractory patient population and may provide an opportunity to address this significant clinical challenge. An open-label extension study of 43 patients who had participated in the randomized trial found that some patients continued to obtain relief of their cancer-related pain with long-term use of the THC:CBD oromucosal spray without increasing their dose of the spray or the dose of their other analgesics.
The Food and Drug Adminstration’s approval of Epidiolex, a medication derived from cannabis, could be life-changing for Americans suffering from certain types of epilepsy. — Jon Cooper, STAT, "New drug approval should force the DEA to rethink cannabis-derived medicines," 26 June 2018 Aside from cannabis, the state appears to have a fairly sunny budget picture. — Adam Ashton, sacbee, "California's marijuana tax collections lag below expectations | The Sacramento Bee," 9 May 2018 The researchers note, however, that abstaining from cannabis for just a few days would likely reverse any blockade. — Beth Mole, Ars Technica, "Here are the types of marijuana best for stress and anxiety, according to users," 20 Apr. 2018 And the best way to do that is by lowering the price of cannabis. — Dan Adams, BostonGlobe.com, "The hidden, high-tech world of communications at Fenway Park," 10 July 2018 The British drugmaker studied the drug in more than 500 patients with hard-to-treat seizures, overcoming numerous legal hurdles to conducting research with cannabis. — Fox News, "Medical milestone: US OKs marijuana-based drug for seizures," 25 June 2018 The British drugmaker studied the drug in more than 500 patients with hard-to-treat seizures, overcoming numerous legal hurdles to conducting research with cannabis. — Matthew Perrone, The Seattle Times, "Medical milestone: US OKs marijuana-based drug for seizures," 25 June 2018 GW Pharmaceuticals says the solution, taken by mouth, is made from a proprietary strain of cannabis designed to maximize a therapeutic component while minimizing components that produce euphoria. — Peter Loftus, WSJ, "FDA Approves First Drug Derived From Marijuana Plant," 25 June 2018 Very often pharmacies with cannabis for sale see long queues forming at the door. — Tamra Santana, Houston Chronicle, "Home building boom continues for Spring, Klein, Tomball and Cypress communities," 14 May 2018
There are hundreds of compounds in marijuana, but scientists believe the one responsible for the drugs' psychoactive effects is tetrahydrocannbinol, or THC. THC binds to cannabinoid receptors throughout the body, and marijuana's "high" comes from THC's binding to brain regions responsible for pleasure, time perception and pain, according to the National Institute on Drug Abuse (NIDA).
Fig. 2. Cannabis sativa. This superb composite plate by artist Elmer Smith, often reproduced at a very small scale and without explanation in marijuana books, is the best scientific illustration of the hemp plant ever prepared. 1. Flowering branch of male plant. 2. Flowering branch of female plant. 3. Seedling. 4. Leaflet. 5. Cluster of male flowers. 6. Female flower, enclosed by perigonal bract. 7. Mature fruit enclosed in perigonal bract. 8. Seed (achene), showing wide face. 9. Seed, showing narrow face. 10. Stalked secretory gland. 11. Top of sessile secretory gland. 12. Long section of cystolith hair (note calcium carbonate concretion at base). Reproduced with the permission of Harvard University, Cambridge, MA.
Individuals who are considering participation in the Industrial Hemp Research Program in Kansas in 2019, whether as a grower, distributor or processor, can now submit a Pre-Application and Pre-Application Research Proposal. This is voluntary, and is not an application for a license, but will provide an opportunity to receive an informal review of your research proposal which can help expedite the process when the full research application is available.
In the 1990s, European firms introduced lines of hemp oil-based personal care products, including soaps, shampoos, bubble baths, and perfumes. Hemp oil is now marketed throughout the world in a range of body care products, including creams, lotions, moisturizers, and lip balms. In Germany, a laundry detergent manufactured entirely from hemp oil has been marketed. Hemp-based cosmetics and personal care products account for about half of the world market for hemp oil (de Guzman 2001).
Cannabis lowers the pressure in the eye that causes optic nerve damage leading to glaucoma. Research has shown conclusively that marijuana users experience lower internal eye pressure while the body metabolizes THC. However, the psychoactive side effects of using THC to treat glaucoma make cannabis a nonviable medication for most people with the disease.
No ongoing clinical trials of Cannabis as a treatment for cancer in humans were identified in a PubMed search. The only published trial of any cannabinoid in patients with cancer is a small pilot study of intratumoral injection of delta-9-THC in patients with recurrent glioblastoma multiforme, which demonstrated no significant clinical benefit.[19,20] In a trial (NCT02255292) conducted in Israel, oral cannabidiol (CBD) was investigated as a single salvage agent for recurrent solid tumors. The study was projected to be completed in 2015; however, no results have been published. A small exploratory phase II study (GWCA1208 Part A [NCT01812603]) was conducted in the United Kingdom that used nabiximols, a 1:1 ratio of THC:CBD in a Cannabis-based medicinal extract oromucosal spray, in conjunction with temozolomide in treating patients with recurrent glioblastoma multiforme. The study enrolled 21 patients. Final results have not been published.
Another field in which CBD is creating a buzz is in the area of mood disorders like anxiety and depression. Both conditions have been treated with a variety of medications, courtesy of Big Pharma, that have had varying levels of success. Again, the long list of side effects can be off-putting to someone who just wants to get through the day without the sweaty tension of anxiety or the gray haze of depression.
And without high-quality trials, experts don’t know how much is best for a given purpose. The staff at Roth’s dispensary told her, “Try some once or twice a day and see what happens.” (Half a dropper’s worth was a good amount for her.) One thing scientists feel confident about is that CBD is not dangerous. It won’t damage vital organs even at doses as high as 5,000 mg a day, Marcu says, and nobody has died from simply overdosing on a cannabis product.
Jump up ^ Devinsky, Orrin; Cilio, Maria Roberta; Cross, Helen; Fernandez-Ruiz, Javier; French, Jacqueline; Hill, Charlotte; Katz, Russell; Di Marzo, Vincenzo; Jutras-Aswad, Didier; Notcutt, William George; Martinez-Orgado, Jose; Robson, Philip J.; Rohrback, Brian G.; Thiele, Elizabeth; Whalley, Benjamin; Friedman, Daniel (22 May 2014). "Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders". Epilepsia. 55 (6): 791-802. doi:10.1111/epi.12631. PMC 4707667. PMID 24854329.
Yet the DEA has stated unequivocally that it considers CBD to be illegal under the Controlled Substances Act. “CBD derived from the cannabis plant is controlled under Schedule I of the CSA because it is a naturally occurring constituent of marijuana,” Joseph Rannazzisi, the deputy assistant administrator of the DEA, told a congressional panel in June. “While there is ongoing research into a potential medical use of CBD, at this time, CBD has no currently accepted medical use in the USA.” Moreover, DEA spokesman Eduardo Chavez told the New Republic that Medical Marijuana, Inc.’s in-house opinion with regards to CBD has no merit. “The bottom line,” Chavez said, “is the oil is part of the marijuana plant, and the marijuana plant is currently a Schedule I controlled substance under federal law.”
Marijuana, also called pot, weed, ganja, mary jane, and a host of other nicknames, is made from the Cannabis plant, which has three species: Cannabis sativa; Cannabis indica and Cannabis ruderalis. The flowering plant, which can grow to 16 feet (5 meters) high, likely originated in the Central Asian steppe, near the Altai or Tian Shian Mountains, and was first cultivated in China and India, according to "Cannabis and Cannabinoids: Pharmacology, Toxicology and Therapeutic Potential," (Routledge, 2002).